|CDK2 (Cell-free assay)||CDK5 (Cell-free assay)||CDK1 (Cell-free assay)||CDK9 (Cell-free assay)|
|1 nM||1 nM||3 nM||4 nM|
|In vitro (25°C)||DMSO||26 mg/mL heating (65.57 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||8 mg/mL heating (20.17 mM)|
|In vivo||15% Captisol||6 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||25.22 mL||126.1 mL||252.21 mL|
|0.5 mM||5.04 mL||25.22 mL||50.44 mL|
|1 mM||2.52 mL||12.61 mL||25.22 mL|
|5 mM||0.5 mL||2.52 mL||5.04 mL|
*The above data is based on the productmolecular weight 396.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
R547 is a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) (Ki = 1, 3, and 1 nM for CDK1, CDK2, …
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 2…
PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity ag…
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle p…
BMS-265246 is a potent new pyra- zolopyridine inhibitor of cdk2/cyclin E and cdk1/cyclin B, as well as cdk4/cyclin D.
Roscovitine (Seliciclib) is a CDK inhibitor that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9.